Dr. Aledort is a chaired Professor of Medicine at the Mount Sinai School of Medicine. He was educated and trained at Albert Einstein College of Medicine, Universities of Rochester and Virginia, and spent two years at the National Institute of Health. He has spent his career in the area of bleeding disorders.
He has served as consultant to the World Health Organization, Pan American Health Organization, House Ways & Means Committee. He has chaired and/or been a member of the practice committees of the American Society of Hematology and American College of Physicians.
He has written more than 400 articles on several aspects of bleeding and clotting disorders. Emphasis has been on the supply availability and affordability of blood products. He has been involved in developing health care programs and their underwriting in developing nations. Dr. Aledort has consulted for CSL Behring, American Red Cross, and Baxter BioScience.
He has received the Lifetime Achievement Awards from the Hemostasis and Thrombosis Research Society and from the Albert Einstein College of Medicine.
- Aledort LM. Off-Label Use of Recombinant Activated Factor VII -Safe or Not Safe? N Engl J Med 2010; 363: 19: 1853-1854.
- Aledort LM. Another role for the VW molecule. Haemophilia 2012; 18: 246-247.
- Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-2192.